Enovis (NYSE:ENOV) Insider Oliver Engert Purchases 750 Shares

Enovis Corporation (NYSE:ENOV) insider Oliver Engert bought 750 shares of Enovis stock in a transaction that occurred on Friday, March 6th. The shares were acquired at an average cost of $24.41 per share, for a total transaction of $18,307.50. Following the completion of the transaction, the insider directly owned 45,640 shares in the company, valued at $1,114,072.40. This represents a 1.67% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Oliver Engert also recently made the following trade(s):

• On Monday, March 9th, Oliver Engert purchased 1,000 shares of Enovis stock. The stock was acquired at an average price of $23.39 per share, with a total value of $23,390.00.
• On Wednesday, March 4th, Oliver Engert purchased 250 shares of Enovis stock. The stock was acquired at an average cost of $25.10 per share, with a total value of $6,275.00.
• On Tuesday, March 3rd, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were acquired at an average price of $24.77 per share, for a total transaction of $24,770.00.
• On Friday, February 27th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were bought at an average price of $25.50 per share, for a total transaction of $25,500.00.

Enovis Stock Performance

Shares of Enovis stock traded down $0.79 during midday trading on Tuesday, hitting $23.87. The company had a trading volume of 975,171 shares, compared to its average volume of 1,154,731. The company has a fifty day simple moving average of $23.97 and a 200 day simple moving average of $27.93. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -1.15 and a beta of 1.46. The company has a quick ratio of 1.04, a current ratio of 2.02 and a debt-to-equity ratio of 0.85. Enovis Corporation has a 12-month low of $21.00 and a 12-month high of $40.69.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The company had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. During the same quarter in the previous year, the firm earned $0.98 EPS. Enovis’s revenue was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts predict that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enovis

Several hedge funds have recently added to or reduced their stakes in the business. Capital Fund Management S.A. purchased a new stake in shares of Enovis in the second quarter worth about $1,682,000. Impax Asset Management Group plc grew its holdings in Enovis by 47.5% during the third quarter. Impax Asset Management Group plc now owns 310,630 shares of the company’s stock worth $9,425,000 after acquiring an additional 100,000 shares during the period. Assenagon Asset Management S.A. purchased a new position in Enovis during the third quarter valued at approximately $4,045,000. Osaic Holdings Inc. lifted its holdings in Enovis by 56.0% in the second quarter. Osaic Holdings Inc. now owns 139,727 shares of the company’s stock valued at $4,382,000 after acquiring an additional 50,156 shares during the period. Finally, Rhumbline Advisers lifted its holdings in Enovis by 32.4% in the second quarter. Rhumbline Advisers now owns 172,341 shares of the company’s stock valued at $5,405,000 after acquiring an additional 42,138 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ENOV has been the topic of several research reports. Zacks Research raised Enovis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 4th. Needham & Company LLC boosted their price target on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. UBS Group reissued a “buy” rating and issued a $50.00 price objective on shares of Enovis in a report on Monday, January 5th. Evercore restated an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Finally, Canaccord Genuity Group decreased their target price on Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Enovis has an average rating of “Moderate Buy” and a consensus price target of $47.43.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.